Extended indication

Multiple Myeloom Relapsed and Refractory

Therapeutic value

No judgement yet

Registration phase

Clinical trials

Product

Active substance

BB2121

Domain

Oncology and Hematology

Reason of inclusion

New medicine (specialité)

Main indication

Multiple Myeloma

Extended indication

Multiple Myeloom Relapsed and Refractory

Manufacturer

Celgene

Mechanism of action

CAR-T therapy

Route of administration

Intravenous

Therapeutical formulation

Intravenous drip

Budgetting framework

Intermural (MSZ)

Additional comments
CAR-T

Registration

Registration route

Centralised (EMA)

Particularity

New medicine with Priority Medicines (PRIME)

Submission date

2020

Expected Registration

2021

Registration phase

Clinical trials

Therapeutic value

Therapeutic value

No judgement yet

Duration of treatment

one-off

Dosage per administration

150 - 450 x 10^6 CAR+ T cells

References
KARMMA 3 NCT03651128

Expected patient volume per year

References
NKR
Additional comments
Zo'n 1200 patiënten komen jaarlijks in aanmerking voor een behandeling tegen MM. Gezien het hier gaat om "Relapsed and Refractory" patiënten zal slechts een deel van deze patiënten in aanmerking komen.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension

No

References
AdisInsight

Other information

There is currently no futher information available.